Clinical Trials in Hungary

• A study to evaluate the benefit and safety of Luspatercept (ACE-536) in adults with myeloproliferative neoplasm-associated myelofibrosis on … Ended
  2023-507890-17-00 Phase III Anemia associated with myeloproliferative neoplasm (MPN)-ass… Celgene Corp.
• This is a Global Study of Neoadjuvant-Adjuvant Durvalumab or Placebo and FLOT Chemotherapy Followed by Adjuvant Durvalumab or Placebo in Pat… Ended
  2023-507338-26-00 Phase III Histologically documented gastric or gastroesophageal juncti… Astrazeneca AB
• A long-term study to assess the safety and efficacy of nemolizumab (CD14152) in subjects with prurigo nodularis (PN) Ended
  2024-514502-31-00 Phase III Prurigo Nodularis Galderma S.A.
• Phase 3 Study of MRTX849 vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation Ended
  2023-507263-19-00 Phase III Advanced Non-Small Cell Lung Cancer Mirati Therapeutics Inc.
• A clinical study of different treatments for kidney cancer (MK-3475-03B) Ended
  2023-506839-15-00 Phase I/II Renal cell carcinoma Merck Sharp & Dohme LLC
• A Phase 3 Trial of Epcoritamab vs Investigator’s Choice Chemotherapy in R/R DLBCL Ended
  2023-504830-23-00 Phase III B-cell Lymphoma Genmab A/S
• A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared with Teriflunomide in Adult Patients with Relapsing Multiple Sclerosis Ended
  2022-502609-14-00 Phase III Relapsing multiple sclerosis (RMS) F. Hoffmann-La Roche AG
• Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed … Ended
  2023-504959-27-00 Phase III Participants with Limited Stage-Small Cell Lung Cancer, who … Merck Sharp & Dohme LLC
• A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Pa… Ended
  2023-506911-16-00 Phase III ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE LOCALLY ADVANCED O… F. Hoffmann-La Roche AG
• Study of Trastuzumab Deruxtecan (DS-8201a, T-DXd) versus Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Breast Ca… Ended
  2024-516653-44-00 Phase III HER2-Low, Hormone Receptor Positive Breast Cancer which has … AstraZeneca AB
• A Study to compare the efficacy of Risankizumab and Utsekinumab in Subjects with Moderately to Severe Active Crohns Disease Ended
  2022-501645-70-00 Phase III Crohns Disease Abbvie Deutschland GmbH & Co. KG
• A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared with Ocrelizumab in Adult Patients with Primary Progressive Multiple Sc… Ended
  2022-502611-10-00 Phase III Primary Progressive Multiple Sclerosis (PPMS) F. Hoffmann-La Roche AG
• Apalutamide, Radiotherapy and LHRH Agonist in High-Risk Hormone-Sensitive Prostate Cancer Patients Assessed by PSMA-PET Ended
  2023-505852-23-00 Phase III High risk recurrent prostate cancer previously treated with … Janssen - Cilag International
• A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sc… Ended
  2023-506515-18-00 Phase III Primary Progressive Multiple Sclerosis (PPMS) F. Hoffmann-La Roche AG
• A Phase 2, Open-Label, Multi-Center Study of Venetoclax in Combination with Carfilzomib and Dexamethasone in Subjects with Relapsed or Refra… Ended
  2023-505659-27-00 Phase II Multiple Myeloma AbbVie Deutschland GmbH & Co. KG
• A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults with Relapsing Multiple Sclerosis Ended
  2023-506467-34-00 Phase III Relapsing Multiple Sclerosis (MS) F. Hoffmann-La Roche AG
• An open study for participants who have been on darolutamide treatment in any other Bayer study Ended
  2022-502084-38-00 Phase III Cancer Bayer Consumer Care AG
• A Phase 3 Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment … Ended
  2023-506365-64-00 Phase III Deleterious Germline or Somatic Homologous Recombination Rep… Janssen - Cilag International
• A Randomized, Open-label Phase 3 Study of Combination Amivantamab and CarboplatinPemetrexed Therapy, Compared with Carboplatin-Pemetrexed, i… Ended
  2023-506033-29-00 Phase III EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-S… Janssen - Cilag International
• A Clinical Trial to evaluate the Efficacy and Safety of of Oral Paclitaxel (DHP107) Compared to IV Paclitaxel as First-line Therapy in Patie… Ended
  2024-517090-24-00 Phase II/III Recurrent or Metastatic HER2 Negative Breast Cancer Daehwa Pharmaceutical Co. Ltd.
• Long-term study to assess the safety and efficacy of Nemolizumab in subjects with Atopic Dermatitis Ended
  2024-514404-13-00 Phase III Atopic Dermatitis Galderma S.A.
• A Clinical Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients … Ended
  2023-506576-27-00 Phase III EGFR-mutated locally advanced or metastatic Non Small Cell L… Janssen - Cilag International
• A Study Evaluating the Efficacy and Safety of Inavolisib Plus Palbociclib and Fulvestrant versus Placebo Plus Palbociclib and Fulvestrant in… Ended
  2023-505812-39-00 Phase III HR+/HER2-Negative Locally Advanced or Metastatic Breast canc… F. Hoffmann-La Roche AG
• An open-label clinical trial evaluating enfortumab vedotin in combination with pembrolizumab versus chemotherapy alone in previously untreat… Ended
  2023-503421-19-00 Phase III Urothelial cancer Seagen Inc.

Showing 793–816 of 1,251 trials